Evoke Pharma, Inc. (EVOK) Earnings History
Net Loss14 years of earnings data (2011–2024) · Currently unprofitable on a TTM basis
Loading earnings history...
Evoke Pharma, Inc. (EVOK) Earnings Overview
As of June 29, 2026, Evoke Pharma, Inc. (EVOK) reported trailing twelve-month net income of -$5M, reflecting +90.0% year-over-year growth. The company earned $-2.04 per diluted share over the past four quarters, with a net profit margin of -52.2%.
Looking at the long-term picture, EVOK's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2012.
Evoke Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRPO (-$1M net income, -26.9% margin), AYTU (-$34M net income, -20.4% margin), TLSA (-$35M net income), EVOK has room to improve margins relative to the peer group. Compare EVOK vs PRPO →
EVOK Earnings vs Peers
Earnings metrics vs comparable public companies
EVOK Historical Earnings Data (2011–2024)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | +31.3% | -$5M | $-2.81 | -52.2% | -50.8% |
| 2023 | -$8M | +5.3% | -$7M | $-27.97 | -150.4% | -143.4% |
| 2022 | -$8M | +3.7% | -$8M | $-31.16 | -327.8% | -310.4% |
| 2021 | -$9M | +35.1% | -$8M | $-40.40 | -527.7% | -503.8% |
| 2020 | -$13M | -84.6% | -$13M | $-74.91 | -57144.5% | -56678.3% |
| 2019 | -$7M | +5.8% | -$7M | $-45.84 | - | - |
| 2018 | -$8M | +38.1% | -$8M | $-65.62 | - | - |
| 2017 | -$12M | -13.8% | -$11M | $-118.21 | - | - |
| 2016 | -$11M | +11.3% | -$11M | $-165.75 | - | - |
| 2015 | -$12M | +8.5% | -$12M | $-269.13 | - | - |
| 2014 | -$13M | -367.0% | -$13M | $-316.23 | - | - |
| 2013 | -$3M | -40.6% | -$3M | $-172.49 | - | - |
| 2012 | -$2M | +16.0% | -$2M | $-234.27 | - | - |
| 2011 | -$2M | - | -$2M | $-304.11 | - | - |
Download Data
Export EVOK earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EVOK — Frequently Asked Questions
Quick answers to the most common questions about buying EVOK stock.
What is EVOK earnings per share (EPS)?
EVOK trailing twelve-month (TTM) diluted EPS is $-2.04, reflecting +90.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2024 is available in the table on this page.
What is Evoke Pharma, Inc.'s net income?
Evoke Pharma, Inc. (EVOK) trailing twelve-month net income is $-5M as of 2024. Earnings grew +90.0% year-over-year.
Is EVOK profitable?
EVOK is not currently profitable on a TTM basis, reporting a net loss of $-5M. Net margin is -52.2%. Investors should monitor for a return to profitability.
What is EVOK's earnings growth rate?
EVOK compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2024.
What are EVOK's profit margins?
Evoke Pharma, Inc. net profit margin is -52.2%, operating margin is -50.8%, and gross margin is +96.5%. Below-average margins reflect competitive or cost pressures. Return on Equity is -240.1%.
Is EVOK growing earnings?
Yes, EVOK earnings are accelerating — EPS growth of +90.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-5M. Earnings momentum is strengthening.
What was EVOK's best earnings year?
Evoke Pharma, Inc.'s highest annual net income on record is $-2M, achieved in fiscal year 2012. Earnings history on this page spans 2011 to 2024 and includes all annual and quarterly figures.
What were EVOK's earnings last quarter?
EVOK's most recent reported quarter was Q3 2025. Net income was $-1M with diluted EPS of $-0.45. For a full breakdown of all quarters, see the quarterly earnings table on this page.